Buck Wealth Strategies LLC Acquires 7,669 Shares of Amgen Inc. (NASDAQ:AMGN)

Buck Wealth Strategies LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 37.7% during the fourth quarter, Holdings Channel reports. The firm owned 28,006 shares of the medical research company’s stock after purchasing an additional 7,669 shares during the quarter. Buck Wealth Strategies LLC’s holdings in Amgen were worth $7,300,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the company. Silver Oak Securities Incorporated raised its holdings in Amgen by 18.8% in the 4th quarter. Silver Oak Securities Incorporated now owns 1,691 shares of the medical research company’s stock worth $439,000 after purchasing an additional 268 shares during the period. YANKCOM Partnership bought a new position in shares of Amgen in the fourth quarter worth approximately $341,000. Centennial Wealth Advisory LLC increased its stake in shares of Amgen by 6.6% in the fourth quarter. Centennial Wealth Advisory LLC now owns 1,347 shares of the medical research company’s stock worth $351,000 after purchasing an additional 83 shares in the last quarter. Trilogy Capital Inc. raised its position in shares of Amgen by 8.8% during the 4th quarter. Trilogy Capital Inc. now owns 10,928 shares of the medical research company’s stock valued at $2,848,000 after purchasing an additional 886 shares during the period. Finally, Onyx Bridge Wealth Group LLC lifted its stake in shares of Amgen by 4.2% during the 4th quarter. Onyx Bridge Wealth Group LLC now owns 1,422 shares of the medical research company’s stock valued at $371,000 after buying an additional 57 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AMGN shares. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Citigroup cut their price objective on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Leerink Partners lowered their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $314.83.

Amgen Stock Performance

AMGN stock opened at $307.81 on Thursday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a market cap of $165.46 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The business’s fifty day simple moving average is $271.69 and its two-hundred day simple moving average is $303.55. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Analysts predict that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.